相关实验视频

Updated: May 30, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在经过手术后复发性肺形癌患者的免疫治疗延长生存期

Wakako Nagase¹, Yujin Kudo¹, Jun Matsubayashi²

¹Department of Surgery, Tokyo Medical University, Japan.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|January 28, 2025

概括

免疫检查点抑制剂 (ICI) 显著改善了复发性肺形癌患者的生存率. 这种侵袭性癌症亚型受益于ICI,特别是高PD-L1表达,在复发后提供更好的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
肺部医学肺部医学

背景情况:

肺形癌 (PPC) 是一种罕见的,激进的非小细胞肺癌 (NSCLC) 亚型.
PPC表现出不良预后,早期复发和对传统疗法的耐药性.
对复发性PPC的新疗法进行研究至关重要.

研究的目的:

评估免疫检查点抑制剂 (ICI) 在患有复发性肺形癌的患者中的疗效.
评估ICI在PPC术后复发后对生存结果的影响.

主要方法:

对71名经过肺切除的PPC患者 (2008-2022) 的回顾性分析.
对临床病理学数据,PD-L1表达和复发性疾病的治疗结果的审查.
复发后接受ICI治疗和不接受ICI治疗的患者的生存率的比较.

主要成果:

在PPC患者中观察到高PD-L1表达 (87%) 和5年OS率为48.6% .
术后复发发生在54%的患者中,其中26%接受免疫疗法 (ICI).
治疗ICI显著增加了整体应答率 (50%vs7%) 和复发后延长的中位生存时间 (83.9vs10.1个月).

结论:

免疫检查点抑制剂 (ICI) 在复发性肺形癌中显示出显著的生存益处.
高PD-L1表达可能预测在这种积极的NSCLC亚型中对ICI的更好的反应.
ICI代表了管理复发性PPC的关键治疗选择,需要密切跟踪.

关键词:

免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.非小细胞肺癌是非小细胞肺癌.在PD-L1中.肺形性肺癌 (PLMCC) 是一种肺癌.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...